Hope this NR paves the way for your I'm led to believe there will be another analyst report coming
out first week in February.
DiagnoCure's ImmunoCyt is adopted by Laboratory Corp.
DiagnoCure Inc CUR
Shares issued 17,498,032 Jan 31 close $1.79
Wed 31 Jan 2001 News Release
Mr. Pierre Desy reports
DiagnoCure's bladder cancer test, ImmunoCyt, has been adopted by Laboratory
Corporation of America Holdings. This event furthers DiagnoCure's
penetration into the U.S. cancer diagnostics market.
LabCorp is one of the largest independent commercial reference laboratories
in the United States and a world leader in finding and adopting innovative
diagnostics in the fields of cytology and oncology. The adoption of
ImmunoCyt by LabCorp was made possible through the efforts of DiagnoCure's
U.S. marketing and distribution partner, DAKO Corporation.
"ImmunoCyt is increasingly finding acceptance and approval in the U.S.
market and subsequently gaining market penetration. ImmunoCyt was only
introduced to the United States in September of last year, and we are
extremely pleased with the progress achieved thus far," said DiagnoCure
president and chief executive, Pierre Desy. "Together with our partner,
DAKO, we will continue to pursue similar arrangements with other leading
U.S. reference laboratories."
ImmunoCyt is used by pathologists in conjunction with classic urine
cytology for the monitoring of disease recurrence. Results from clinical
studies have shown that ImmunoCyt, when combined with cytology, improves
the sensitivity rate of early-stage bladder cancer detection to more than
90 per cent.
Danish private company DAKO is a leading global market leader in the
marketing and distribution of diagnostic products for the pathology
laboratory. As a pioneer in pharmacoDiagnostics -- therapy-linked
diagnostics tools - DAKO's expanding product line includes cell and tissue
cancer diagnostics, innovative detection systems, advanced instrumentation,
flow cytometry and molecular systems. DAKO Corporation is the company's
U.S. subsidiary, located in Carpinteria.
LabCorp is a national U.S. clinical laboratory and a leader in the
commercialization of innovative diagnostic technologies. With over 2,000
clinical tests ranging from simple blood analysis to sophisticated genomic
tests, LabCorp possesses a comprehensive test menu for the evaluation,
treatment and monitoring of bladder cancer uses diagnostic capabilities
ranging from traditional methods such as cytology to leading-edge molecular
genetic technologies.
(c) Copyright 2001 Canjex Publishing Ltd. stockwatch.com |
